Dr. hab. Marcin Poręba's team at Wroclaw University of Technology focuses on developing a new class of therapeutics known as antibody-drug conjugates (ADCs).
These innovative compounds aim to precisely target pathological features associated with Alzheimer's disease, potentially leading to breakthrough results by minimizing side effects and enhancing treatment efficacy.
The project has received nearly 5 million PLN (1.2 million EUR) in funding from the National Science Centre.
According to Professor Marcin Poręba, these conjugates will target proteins responsible for the progression of Alzheimer's disease.
Antibody-drug conjugates, already showing promise in oncology, consist of an antibody, a linker, and a drug, with the antibody serving both as a therapeutic agent and a carrier for the toxic drug, which is released in the tumor environment.
(m p)
Source: PWr/PAP